Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOE regimen in relapsed or refractory advanced male germ cell tumors
ChiCTR2300077760Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, oxaliplatin and eribulin in germ cell tumor (GCT), seminoma, non-seminomatous germ cell tumor (NSGCT) and 1 more, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Favorable best response rate. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
gemcitabineoxaliplatineribulin
03
Conditions
germ cell tumor (GCT)seminomanon-seminomatous germ cell tumor (NSGCT)Mixed germ cell cancer (MGCT)
Beyond the preview
Go deeper on ChiCTR2300077760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077760.